Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data
This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without m...
Saved in:
Published in | Acta dermato-venereologica Vol. 105; p. adv41244 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Sweden
MJS Publishing, on behalf of the Society for Publication of Acta Dermato-Venereologica
24.04.2025
Medical Journals Sweden |
Subjects | |
Online Access | Get full text |
ISSN | 0001-5555 1651-2057 1651-2057 |
DOI | 10.2340/actadv.v105.41244 |
Cover
Abstract | This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0–11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland. |
---|---|
AbstractList | This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0–11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland. This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0–11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland. Analysis of real-world data provides insights into characteristics of patients with moderate-to-severe atopic dermatitis and the medical treatment they receive. This nationwide study identified and analysed 68,216 patients with moderate-to-severe atopic dermatitis in Finland during the years 2016–2020. Their healthcare resource use was compared with that in a reference sample of 338,325 people without moderate-to-severe atopic dermatitis. Findings demonstrate that moderate-to-severe atopic dermatitis is associated with increased disease burden and healthcare resource use in all age groups. It is therefore imperative to aim for improved control of atopic dermatitis. This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0-11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland.This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0-11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland. |
Author | Korhonen, Laura Remitz, Anita Nortamo, Pekka Gittens, Beatrice Von Arx, Lill-Brith Oinonen, Lasse Porsdal, Vibeke Iso-Mustajärvi, Ilona Prami, Tuire Peltonen, Essi J. |
Author_xml | – sequence: 1 givenname: Anita surname: Remitz fullname: Remitz, Anita – sequence: 2 givenname: Essi J. surname: Peltonen fullname: Peltonen, Essi J. – sequence: 3 givenname: Laura surname: Korhonen fullname: Korhonen, Laura – sequence: 4 givenname: Pekka surname: Nortamo fullname: Nortamo, Pekka – sequence: 5 givenname: Ilona surname: Iso-Mustajärvi fullname: Iso-Mustajärvi, Ilona – sequence: 6 givenname: Tuire surname: Prami fullname: Prami, Tuire – sequence: 7 givenname: Lasse surname: Oinonen fullname: Oinonen, Lasse – sequence: 8 givenname: Beatrice surname: Gittens fullname: Gittens, Beatrice – sequence: 9 givenname: Lill-Brith surname: Von Arx fullname: Von Arx, Lill-Brith – sequence: 10 givenname: Vibeke surname: Porsdal fullname: Porsdal, Vibeke |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40271985$$D View this record in MEDLINE/PubMed |
BookMark | eNpVks1uEzEUhS1URH_gAdggL9lM8O_MmA2K0pZWKlCJdm059p3E1cQOthOpPAjPi5OUinpj3XPP_a5kn1N0FGIAhN5TMmFckE_GFuO2ky0lciIoE-IVOqGtpA0jsjtCJ4QQ2sh6jtFpzg-1ZJL2b9CxIKyjqpcn6M9saVLlQPK_fVjgW1M8hJKxCQ7fJTBlVcudXC0hYx_wt-ggmQJNiU2GLSTA0xLX3uJzSKs6X_zed-nDWCmf8RTfxvVmrJ0YmrnJ4PDPsnGP-D7vVn7fN8yIr8CMZYnPTTFv0evBjBnePd1n6P7y4m521dz8-Ho9m940VjBSGsdZr4RwLVekVwPQgXLimGPGSuKMdG0_SMaUasVg5sAGOSgGXW-tJfO-6_gZuj5wXTQPep38yqRHHY3XeyGmhTapeDuC7oStA7bnneBCQtu3RjCuWDfnrnMWKuvLgbXezFdQlVCSGV9AX3aCX-pF3GrKiKCd6ivh4xMhxV8byEWvfLYw1meEuMmaUyWYVETKav3w_7LnLf9-throwWBTzDnB8GyhRO_Sow_p0bv06H16-F-eZrt3 |
Cites_doi | 10.1111/ijd.15912 10.1016/j.jaad.2022.01.009 10.1111/all.13401 10.1002/ski2.232 10.2340/actadv.v103.4447 10.2340/00015555-3165 10.1016/j.clindermatol.2021.08.021 10.1080/19490976.2022.2096995 10.2340/00015555-3257 10.2340/actadv.v102.2287 10.2340/00015555-3510 10.1016/j.jid.2017.03.029 10.12788/cutis.0831 10.1007/s40257-018-0383-4 10.1111/bjd.18296 10.1007/s40257-019-00453-7 10.1080/21556660.2019.1619570 10.5826/dpc.1104a146 10.2340/00015555-3369 10.1097/DER.0000000000000895 10.1002/jvc2.247 10.1111/jdv.18429 10.1016/j.jaad.2016.05.028 10.1016/S0140-6736(20)31286-1 |
ContentType | Journal Article |
Copyright | 2025 The Author(s) 2025 |
Copyright_xml | – notice: 2025 The Author(s) 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.2340/actadv.v105.41244 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals (WRLC) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1651-2057 |
ExternalDocumentID | oai_doaj_org_article_74c773c8374345e686a423927b3d7dce PMC12041798 40271985 10_2340_actadv_v105_41244 |
Genre | Journal Article Observational Study |
GeographicLocations | Finland |
GeographicLocations_xml | – name: Finland |
GroupedDBID | --- 23M 36B 5GY 5RE 5VS 6J9 AAFWJ AAYXX ABDBF ABOCM ACGFO ACUHS AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS B0M CITATION CS3 DIK E3Z EAD EAP EBC EBD EBS EBX EJD EMB EMK EMOBN ESX F5P FIJ GROUPED_DOAJ GX1 H13 HF~ IPNFZ KQ8 L7B MSJ OK1 P2P P6G RIG RNS RPM SV3 TR2 TUS ~8M CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c420t-d328944d639089fe1f130d2d2ac50da5d68f5229964fabe2f5f92e78ccc0b8773 |
IEDL.DBID | DOA |
ISSN | 0001-5555 1651-2057 |
IngestDate | Wed Aug 27 01:19:00 EDT 2025 Thu Aug 21 18:26:37 EDT 2025 Wed Jul 02 04:50:10 EDT 2025 Thu May 29 04:59:36 EDT 2025 Sun Jul 06 05:03:56 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | https://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c420t-d328944d639089fe1f130d2d2ac50da5d68f5229964fabe2f5f92e78ccc0b8773 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Retired; affiliation at time study was conducted. |
OpenAccessLink | https://doaj.org/article/74c773c8374345e686a423927b3d7dce |
PMID | 40271985 |
PQID | 3194259055 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_74c773c8374345e686a423927b3d7dce pubmedcentral_primary_oai_pubmedcentral_nih_gov_12041798 proquest_miscellaneous_3194259055 pubmed_primary_40271985 crossref_primary_10_2340_actadv_v105_41244 |
PublicationCentury | 2000 |
PublicationDate | 20250424 |
PublicationDateYYYYMMDD | 2025-04-24 |
PublicationDate_xml | – month: 4 year: 2025 text: 20250424 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | Sweden |
PublicationPlace_xml | – name: Sweden |
PublicationTitle | Acta dermato-venereologica |
PublicationTitleAlternate | Acta Derm Venereol |
PublicationYear | 2025 |
Publisher | MJS Publishing, on behalf of the Society for Publication of Acta Dermato-Venereologica Medical Journals Sweden |
Publisher_xml | – name: MJS Publishing, on behalf of the Society for Publication of Acta Dermato-Venereologica – name: Medical Journals Sweden |
References | 108820 108821 108822 108816 108817 108818 108819 108812 108813 108814 108815 108830 108831 108832 108833 108827 108828 108829 108823 108824 108825 108826 108841 108842 108843 108844 108840 108838 108839 108834 108835 108836 108837 108852 108810 108811 108850 108851 108809 108805 108849 108806 108807 108808 108845 108802 108846 108803 108847 108804 108848 |
References_xml | – ident: 108824 doi: 10.1111/ijd.15912 – ident: 108844 doi: 10.1016/j.jaad.2022.01.009 – ident: 108811 doi: 10.1111/all.13401 – ident: 108814 doi: 10.1002/ski2.232 – ident: 108842 doi: 10.2340/actadv.v103.4447 – ident: 108809 doi: 10.2340/00015555-3165 – ident: 108815 doi: 10.1002/ski2.232 – ident: 108846 doi: 10.1016/j.clindermatol.2021.08.021 – ident: 108847 doi: 10.1080/19490976.2022.2096995 – ident: 108805 doi: 10.2340/00015555-3257 – ident: 108837 doi: 10.2340/actadv.v102.2287 – ident: 108812 doi: 10.2340/00015555-3510 – ident: 108810 doi: 10.1111/all.13401 – ident: 108832 doi: 10.1016/j.jid.2017.03.029 – ident: 108851 doi: 10.12788/cutis.0831 – ident: 108813 doi: 10.2340/00015555-3510 – ident: 108841 doi: 10.2340/actadv.v103.4447 – ident: 108807 doi: 10.1007/s40257-018-0383-4 – ident: 108849 doi: 10.1111/bjd.18296 – ident: 108817 doi: 10.1007/s40257-019-00453-7 – ident: 108820 doi: 10.1080/21556660.2019.1619570 – ident: 108825 doi: 10.1111/ijd.15912 – ident: 108822 doi: 10.5826/dpc.1104a146 – ident: 108826 doi: 10.2340/00015555-3369 – ident: 108833 doi: 10.1097/DER.0000000000000895 – ident: 108836 – ident: 108838 doi: 10.2340/actadv.v102.2287 – ident: 108804 doi: 10.2340/00015555-3257 – ident: 108840 doi: 10.1002/jvc2.247 – ident: 108827 doi: 10.2340/00015555-3369 – ident: 108831 doi: 10.1016/j.jid.2017.03.029 – ident: 108848 doi: 10.1080/19490976.2022.2096995 – ident: 108806 doi: 10.1007/s40257-018-0383-4 – ident: 108828 doi: 10.1111/jdv.18429 – ident: 108821 doi: 10.1080/21556660.2019.1619570 – ident: 108835 – ident: 108843 doi: 10.1016/j.jaad.2022.01.009 – ident: 108816 doi: 10.1007/s40257-019-00453-7 – ident: 108818 doi: 10.1016/j.jaad.2016.05.028 – ident: 108839 doi: 10.1002/jvc2.247 – ident: 108819 doi: 10.1016/j.jaad.2016.05.028 – ident: 108850 doi: 10.1111/bjd.18296 – ident: 108823 doi: 10.5826/dpc.1104a146 – ident: 108830 – ident: 108802 doi: 10.1016/S0140-6736(20)31286-1 – ident: 108852 doi: 10.12788/cutis.0831 – ident: 108845 doi: 10.1016/j.clindermatol.2021.08.021 – ident: 108834 doi: 10.1097/DER.0000000000000895 – ident: 108803 doi: 10.1016/S0140-6736(20)31286-1 – ident: 108808 doi: 10.2340/00015555-3165 – ident: 108829 doi: 10.1111/jdv.18429 |
SSID | ssj0002518 |
Score | 2.4141834 |
Snippet | This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | adv41244 |
SubjectTerms | Adolescent Adrenal Cortex Hormones - therapeutic use Adult Age Factors Aged Atopic dermatitis Child Child, Preschool clinical practice patterns Comorbidity Databases, Factual Dermatitis, Atopic - diagnosis Dermatitis, Atopic - drug therapy Dermatitis, Atopic - epidemiology Dermatologic Agents - administration & dosage Dermatologic Agents - therapeutic use Emollients - therapeutic use Female Finland - epidemiology Humans Infant Infant, Newborn Male Middle Aged observational study Original Report patient characteristics Practice Patterns, Physicians' - trends Severity of Illness Index Young Adult |
Title | Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40271985 https://www.proquest.com/docview/3194259055 https://pubmed.ncbi.nlm.nih.gov/PMC12041798 https://doaj.org/article/74c773c8374345e686a423927b3d7dce |
Volume | 105 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NSxwxFA_ioXgptrXt9kNS6KkQzeZjkultq12koHhQ8BYySQYHZFbcUWj_kP69fS-ZXdxS8NI5JoGE-b28j-Tl9wj5LKOxAboYB1vLQEt65r2QTPo2TE0A2Gt873x6Vp1cqh9X-upRqS_MCSv0wOXHHRoVjJEB4igllU6VrTxy1gnTwDQxJNS-vOarYGrUwWC1iw6GYFnDV-4zhVT80IfBx4eDB3AsDrD0stqwSJm4_1_e5t9Jk4-s0HyXPB_dRzory35BtlL_kjw7HS_IX5HfR2sC5l9glOh5oU1dUt9HerFKKsdmPAhc0q6nuRoaeJxsWDAwk-ku0dmwuO0CPU7Fn-3yuHnXYxbkVzqj5-uqXwytYKSYjfiT5vQDOjJt39Dywoke-8Hvkcv594ujEzaWXmBBCT6wKCEQUyqC_8Jt3aZpC7Yuiih80Dx6HSvbgucGwZJqfZNEq9taJIA9BN5YAOw12e4XfXpLaGNC46tgosZXq1x5k6oQjJQx1bYR1YR8Wf1-d1sYNhxEJoiVK1g5xMplrCbkGwK0Hojk2LkBRMaNIuOeEpkJ-bSC18FmwhsS36fF_dKBPgIdVnOtJ-RNgXs9FQTaZlpb6LEbgrCxls2evrvOhN1TwbHQm333P1b_nuwIrEHMFRPqA9ke7u7TR3CMhmY_74H9fGL1B7hXDaY |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterizing+Patients+and+Treatment+Patterns+in+Moderate-to-severe+Atopic+Dermatitis+in+Finland%3A+A+Population-based+Study+Using+National+Health+Data&rft.jtitle=Acta+dermato-venereologica&rft.au=Remitz%2C+Anita&rft.au=Peltonen%2C+Essi+J.&rft.au=Korhonen%2C+Laura&rft.au=Nortamo%2C+Pekka&rft.date=2025-04-24&rft.issn=0001-5555&rft.eissn=1651-2057&rft.volume=105&rft.spage=adv41244&rft_id=info:doi/10.2340%2Factadv.v105.41244&rft.externalDBID=n%2Fa&rft.externalDocID=10_2340_actadv_v105_41244 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-5555&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-5555&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-5555&client=summon |